Chuck Shih leads Pew’s specialty drugs research initiative, which identifies policy options to help manage drug costs and ensure that patients have access to lifesaving treatments.
Prior to joining Pew, he held a fellowship in health policy at the National Pharmaceutical Council and George Washington University School of Public Health and Health Services.
Shih previously worked at the Centers for Medicare & Medicaid Services, where he was an analyst in the Coverage and Analysis Group and developed Medicare coverage policies for medical devices, pharmaceuticals, and procedures. He also served as a fellow at the Agency for Healthcare Research and Quality, where he advanced and implemented the Healthcare Horizon Scanning System, and served as a project officer for the creation of comparative effectiveness evidence reports and systematic reviews in the Effective Health Care Program.
Shih received a doctorate and master of health science degree from Johns Hopkins Bloomberg School of Public Health and a bachelor’s degree from Johns Hopkins University.
Recent WorkView All
The use of biosimilars—biological products that are highly similar to a biologic drug already approved by the Food and Drug Administration (FDA)—has the potential to reduce drug spending in Medicare Part B,1 which totaled $21.5 billion in 2014.2 However, savings to Medicare will depend on the extent to which biosimilars have lower prices than biologics—which, unlike conventional... Read More
The availability of generic drugs—which can be priced 80 percent lower than their branded equivalents—increases competition and reduces spending on pharmaceuticals. The Generic Pharmaceutical Association estimates that generic drugs generated $254 billion in savings in 2014. Read More
Pharmacists often make drugs for patients whose clinical needs cannot be met by a commercially available product, a practice known as compounding. But should pharmacists compound drugs to reduce costs for patients and the health care system? Read More